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ORIGINAL ARTICLE
Autism-associated Dyrk1a truncation mutants impair neuronal
dendritic and spine growth and interfere with postnatal cortical
development
T Dang1, WY Duan2,5, B Yu3, DL Tong3, C Cheng3, YF Zhang3, W Wu2,6, K Ye2,7, WX Zhang2,8, M Wu1,2, BB Wu1,2, Y An1,2, ZL Qiu3,9 and
BL Wu1,4,9
Autism is a prevailing neurodevelopmental disorder with a large genetic/genomic component. Recently, the dual-speciﬁcity
tyrosine-(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) gene was implicated as a risk factor for autism spectrum disorder (ASD).
We identiﬁed ﬁve DYRK1A variants in ASD patients and found that the dose of DYRK1A protein has a crucial role in various aspects
of postnatal neural development. Dyrk1a loss of function and gain of function led to defects in dendritic growth, dendritic spine
development and radial migration during cortical development. Importantly, two autism-associated truncations, R205X and E239X,
were shown to be Dyrk1a loss-of-function mutants. Studies of the truncated Dyrk1a mutants may provide new insights into the role
of Dyrk1a in brain development, as well as the role of Dyrk1a loss of function in the pathophysiology of autism.
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INTRODUCTION
Autism spectrum disorder (ASD) is a complex, heterogeneous
neurodevelopmental disorder1 with multiple different etiologies.
The heritability of ASD has been estimated to be as high as 90%.2
ASD is usually diagnosed by clinical assessment and the onset of
three core disturbances before 3 years of age: impaired social
interaction, unusual patterns of highly restricted interests and
repetitive behaviors, and language abnormalities.2 The risk of
recurrence for ASD is approximately 2–3%.3
Autism is thought to occur when an array of potential genetic
vulnerabilities, possibly in concert with epigenetic factors and/or
gene–environment interactions, affect neural connectivity and
neurodevelopment.4 To date, we have learned that the symptoms
of autism may arise when some speciﬁc region of the genome
appears to be abnormal; for instance, multiple genetic/genomic
factors have been reported to be associated with autism,
including chromosomal abnormalities, genomic copy number
variants and genetic variants of speciﬁc genes.5–8
Dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1A
(DYRK1A), which is encoded by a gene on human chromosome 21,
is involved in many of the biological processes of neural
development and performs critical functions by phosphorylating
various downstream substrates, including transcription factors,
splice factors and synaptic proteins.9 For example, DYRK1A-
mediated phosphorylation of the P53 protein at Ser15 inhibits cell
proliferation and is therefore associated with cell growth and
differentiation.10 The tau protein and the N-WASP protein affect the
outgrowth of microscopic ﬁbers and actin assembly when they are
phosphorylated by DYRK1A and thereby contribute to the
development of neuronal dendrites and dendritic spines.11–13
Considering the critical contribution of DYRK1A to Down syndrome
(DS),14 numerous studies have focused on the Dyrk1a gain-of-
function model, in which transgenic mice that overexpress
Dyrk1a by 1.5-fold show severe learning and memory
defects.15–17 The dosage imbalance of Dyrk1a led to delayed neural
development.18–20 Previous studies have identiﬁed the molecular
mechanisms by which DYRK1A affects the occurrence of DS and
mental retardation.9,15,21–23 In several recent exome sequencing
studies of ASD patients, some DYRK1A variants were found to be
associated with autism, suggesting that DYRK1A is another risk
factor for ASD.6,24–26
In an exome sequencing pilot study, we identiﬁed several
DYRK1A mutations in ASD patients with intellectual disability (ID)
and developmental delay (DD) (short name ASD/ID/DD or ASD),
consistent with the ﬁndings of other independent studies.27
Furthermore, we screened 892 patients with ASD/ID/DD and/or
epilepsy/seizure for the DYRK1A gene and found additional
variants of DYRK1A (Supplementary Table S1). Using this sequen-
cing approach, a total of 11 novel variants and 1 known mutation
in the coding region were detected, of which 9 variants were
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predicted to alter protein function according to bioinformatics
prediction (Table 1), whereas the other 3 variants were benign.
Given the locations of the DYRK1A variants in the speciﬁc protein
domains, we postulate that those variants may affect DYRK1A
function in three ways: nuclear localization, kinase activity, and
abnormal translation termination that results in truncated DYRK1A
proteins (Table 1 and Figure 1c). Previous reports have suggested
that the R205X mutant acts in the third way.28,29 Owing to the
critical role of Dyrk1a in neural development, we decided to
investigate the role of Dyrk1a in neural development, as well
as whether these Dyrk1a variants have loss- or gain-of-function
effects.
MATERIALS AND METHODS
Selected DYRK1A variants for the neuronal function study
Previously, we collaboratively screened 892 patients at Boston Children’s
Hospital (437 samples of the western population) and the Children’s
Table 1. The genomic and bioinformatics analysis of DYRK1A variants that may be associated with ASD/ID/DD
Exon Nucleotide change Genome position Protein
change
Type Function prediction by bioinformatics
tools
MAF in ASD
patients
MAF in
controls
6 c.355C4T Chr21:38852967 p.H119Y Missense SIFT: possibly damaging
Polyphen: tolerated
MutationTaster: disease causing
PhyloP: highly conserved
0.00151 0
6 c.376G4T Chr21:38852988 p.D126Y Missense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: highly conserved
0.00151 0
6 c.398G4A Chr21:38853010 p.R133Q Missense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: moderately conserved
0.00151 0
7 c.583G4A Chr21:38858835 p.A195T Missense SIFT: possibly damaging
Polyphen: tolerated
MutationTaster: disease causing
PhyloP: weekly conserved
0.00146 0
7 c.613C4T Chr21:38858865 p.R205X Nonsense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: NA
0.00158 0
8 c.715G4T Chr21:38862527 p.E239X Nonsense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: NA
0.00158 0
8 c.777G4T Chr21:38862589 p.L259F Missense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: highly conserved
0.00158 0
11 c.1373G4T Chr21:38877719 p.R458M Missense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: highly conserved
0.00138 0
11 c.1457G4GA Chr21:38877803 p.G486D Missense SIFT: possibly damaging
Polyphen: deleterious
MutationTaster: disease causing
PhyloP: highly conserved
0.00138 0
Abbreviations: ASD, autism spectrum disorder; DD, developmental delay; ID, intellectual disability; MAF, minor allele frequency; NA, not available. Note: (1) The
inheritance pattern of the variants in this table could not be determined because they were de-identiﬁed proband samples and no parental samples were
available for this study, which were indicated in the section of Materials and Methods. (2) The 5 DYRK1A variants in bold in this table (p.R205X, p.E239X, p.
H119Y, p.A195T and p.L259F) were selected to investigate whether these variants may exhibit loss- or gain-of-function effects. (3) The prediction value by
Bioinformatics tools are listed in Supplementary Table S1: DYRK1A variants detected in 892 ASD/ID/DD samples.
Figure 1. Wild-type (WT) Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) overexpression reduced total neurite and
axon length of neurons in primary cultured mouse cortical neurons. (a) The Dyrk1a expression pattern in the cerebral cortex during the
embryonic and postnatal period. (b) Speciﬁc knockdown of endogenous Dyrk1a in the mouse cortical neurons. Immunoblotting of the knock-
down using speciﬁc short hairpin RNA (shRNA) against endogenous DYRK1A protein. The protein marker ladders are shown on the right.
(c) Representation of the speciﬁc locations of missense variants related to autism in the DYRK1A protein structure, with the two truncations
highlighted in red. The ﬁve variants located above the protein structure were included in the additional functional study. The smaller orange
bar shows the NLS (bipartite nuclear localization signal) motif, and the larger bar (blue) represents the protein kinase domain. The black thread
shows the other amino acids making up DYRK1A. (d) The speciﬁc cellular morphology of neurons expressing the CAG vector (as a control),
Dyrk1a RNAi, Dyrk1a WT overexpression, the two truncations (R205X and E239X) and the three missense mutations (H119Y, A195T and L259F).
All neurons were co-labeled with 4,6-diamidino-2-phenylindole (DAPI; to identify nuclei), green ﬂuorescent protein (GFP; to identify overall
neuronal morphology) and SMI 312 (an axonal marker). Scale bar 50 μm. (e, f) The statistical results for the total neurites (e) and axon length
(f) between speciﬁc cell types. The bar graph shows the mean value± s.e.m.; approximately 70 cells from three independent experiments were
counted during the statistical analysis. Unpaired t-test statistical method was used. **Po0.01, ***Po0.001, ****Po0.0001.
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Hospital of Fudan University (455 samples of Han Chinese) with ASD/ID/DD
for DYRK1A. All samples were de-identiﬁed prior to collection under
Institutional Review Board protocols for non-identiﬁable biological speci-
mens, which were deemed ‘leftover’ from patient samples after clinical
tests. Of these, we selected samples with an ASD/ID/DD and/or epilepsy/
seizure diagnosis according to Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition. This study was approved by each institute.
The sequencing experiments were also performed at each institute. For
the bioinformatics analysis of the DYRK1A variants identiﬁed in the screen,
the longest of DYRK1A isoform was used as a reference sequence
(NM_001396.3, NP_001387.2). Considering the high homology between
human and mouse Dyrk1a, we introduced the mouse Dyrk1a cDNA
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(NM_007890.2, NP_031916.1) into our study, and the DYRK1A variants in
the coding region that were identiﬁed in individuals with ASD
corresponded to Dyrk1a (Supplementary Table S2). Variants were classiﬁed
according to DYRK1A protein domains listed in UniProt (http://www.
uniprot.org/).
Supplementary Table S1 lists the variants detected in these patients.
Based on the classiﬁcation of the 11 variants, we selected 5 representative
variants (three missense: H119Y, A195T and L259F; and two nonsense:
R205X and E239X), which covered all three kinds of variants described
previously, to investigate the role of DYRK1A in neurodevelopment, as well
as the effects of these variants on the DYRK1A protein (Figure 1c).
Considering that DYRK1A is highly conserved between human and mouse
(approximately 99% according to protein sequence alignment using the
MegAlign software; Supplementary Figure S1), we used the cDNA of
mouse Dyrk1a rather than of human DYRK1A. The ﬁve variants were
located in the mouse Dyrk1a cDNA, which corresponded to DYRK1A
(Supplementary Table S2).
Clinical information on patients harboring DYRK1A mutations
The patient with R205X was diagnosed with ID and global DD. She
exhibited microcephaly, chronic static encephalopathy and aphasia, oral
motor apraxia, seizure dysmorphism and anxiety. All test results for
karyotyping, fragile X and chromosomal microarray analysis were negative.
The patient with E239X was diagnosed with ASD and global DD. He had a
history of autism, anxiety and developmental coordination disorder, as well
as abnormal electroencephalography but no seizures. Tests results for
karyotyping, fragile X and chromosomal microarray analysis were negative.
The patient with H119Y was diagnosed with PDD-NOS (pervasive
developmental disorder, not otherwise speciﬁed). She had a history of
global DD that was most marked for speech delay, motor delay and motor
coordination disorder, seizure and mild physical dysmorphology. Tests
results for karyotyping, fragile X and chromosomal microarray analysis
were negative. Magnetic resonance imaging and magnetic resonance
spectroscopy were normal. The patient with A195T was diagnosed with
ASD/ID. He had a history of infantile spasms and global DD, with particular
impairments in language, social interaction and repetitive behaviors, mild
ID, complex partial epilepsy with epileptic encephalopathy and anxiety.
Tests results for karyotyping, fragile X and chromosomal microarray
analysis were negative. The patient with L259F was diagnosed with PDD-
NOS and then ASD/ID. He demonstrated extremely low cognitive abilities
and adaptive functioning, consistent with the mild range of ID. He had
anxiety, perseveration and additional upsets and aggressive behavior.
Because the parents of the patients were not available for testing, no other
genetic information was available.
Plasmids
The full-length Dyrk1a ORF was ampliﬁed from the total cDNA of mouse
cortical neurons. Dyrk1a was then inserted into pRK5-Myc, which already
contained a 1xMyc epitope tag (5′-EQKLISEEDL-3′) at the 5′ end. For
immunoﬂuorescence experiments, we cloned Myc-Dyrk1a into pCAGGS-
IRES-green ﬂuorescent protein (GFP). The mutants, including both
missense mutations and the two truncations, were generated using
KOD-Plus, and speciﬁc primers were designed (Supplementary Table S3)
according to the manufacturer’s instructions (#132000; Toyobo, Osaka,
Japan). The mouse Dyrk1a shRNA was directed against the following
sequence, 5′-AGAAGACGATGCATACAGG-3′, which was introduced into the
pSUPER vector.
Lentivirus was provided by BrainVTA (Wuhan, China).
Antibodies
The antibodies used in this study included the following: DYRK1A
(no. 2771; Cell Signaling Technology, Danvers, MA, USA); GAPDH (no.
ab8245; Abcam, Cambridge, UK); Myc epitope tag (no. M20002; Abmart,
Berkeley Heights, NJ, USA); GFP (no. G10362; Invitrogen, Carlsbad, CA, USA),
and SMI 312 (no. SMI-312R; COVANCE, Princeton, NJ, USA).
Cell culture
Embryonic day 15 (E15)–E16 mouse cortical neurons were cultured and
transfected via electroporation with an Amaxa Nucleofector (Amaxa,
Cologne, Germany) at 0 days in vitro (DIV) on cover glasses that had been
coated with a poly-D-lysine solution (1 mg ml− 1 in dd water) according to
the manufacturer’s instructions. After DIV 3, the cells were ﬁxed for further
analysis.
For neurite and axon outgrowth rescue experiments, we co-transfected
each group with two plasmids, using a 1:1 ratio of wild-type (WT) or
mutant forms of Dyrk1a and short hairpin RNAs (shRNAs), via electropora-
tion as described above. Cells were collected for immunoﬂuorescence
analysis after 72 h of in vitro culturing.
Immunoﬂuorescence
Cells were washed with 1 × phosphate-buffered saline (PBS) for 5 min,
ﬁxed in 4% paraformaldehyde (PFA) for 20 min and blocked in 1 × PBS
buffer with 3% bovine serum albumin and 0.1% Triton-X-100 for 60 min at
room temperature (RT). The cells were incubated in primary antibodies
overnight at 4 °C, washed three times in 1 × PBS and then incubated in
secondary antibodies at RT for 90–120 min. The signals were observed via
ﬂuorescence microscopy.
Immunoblotting
For Dyrk1a-speciﬁc expression in the mouse cortex, cortical tissue
homogenates were prepared from the mouse brains at different develop-
mental stages, immersed in RIPA buffer, boiled in 1× sodium dodecyl sulfate
loading buffer and then resolved by 8% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. All of the protein on the gel was
transferred to polyvinylidene ﬂuoride membranes (Amersham Biosciences,
Uppsala, Sweden), and the membranes were blocked with 5% non-fat milk in
Tris-buffered saline and Tween 20 (TBST) buffer for 1 h. The membranes were
then incubated in primary antibodies overnight at 4 °C, washed three times
in TBST and incubated in secondary antibodies for 1 h at RT. The signals were
revealed by horseradish peroxidase reaction using SuperSignal Chemilumi-
nescent Substrate (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Hippocampal slice culture
Postnatal day 5 (P5) Sprague Dawley rats were included in the spine
density study. Hippocampal tissue slices (400 μm) were cultured on
Millicell (0.4 μm; Millipore, Boston, MA, USA) in six-well plates with 1 ml of
slice culture medium as described previously.30,31 The cultured slices were
incubated in 5% CO2 at 37 °C and transfected using a Helios Gene Gun
(Bio-Rad, Hercules, CA, USA) at DIV 2. Bullets were prepared containing
50 μg of plasmid DNA coated on 25 mg of 1.0-μm gold particles (Bio-Rad).
The medium was changed every 2 days. The slices were ﬁxed at DIV 7
in ice-cold 4% PFA. GFP immunostaining was then conducted using
a GFP antibody and an Alexa 488-conjugated secondary antibody (1:1000).
DAPI (4,6-diamidino-2-phenylindole; 1:500) was also used to visualize cell
nuclei.
In utero electroporation
Plasmids encoding WT Dyrk1a, R205X and the empty vector were prepared
in a ﬁnal volume of 15 μl (2 μg μl− 1 plasmid DNA, 0.01% Fast Green and
0.5 μg μl− 1 enhanced GFP) for each pregnant mouse. The plasmids were
then injected into the ventricles of E14.5 mouse brains. Electroporation
(50-ms square pulses at 1000-ms intervals) was performed using an Electro
Square Porator (ECM 830, San Diego, CA, USA) at 30 V.
Mouse pups were harvested at P0, and whole brains were ﬁxed in 4%
PFA for 24 h and sequentially dehydrated in 15% and 30% sucrose
solutions (in 1 × PBS) for448 h. Longitudinal brain sections (30 μm) were
obtained via frozen sectioning for later immunoﬂuorescence experiments
in which GFP immunostaining was performed using a GFP antibody and an
Alexa 488-conjugated secondary antibody (1:1000) to recognize GFP-
positive neurons.
Data analysis
Images were obtained using a Nikon E80i ﬂuorescence microscope
(Nikon, Tokyo, Japan) equipped with a × 20 objective (for neurite
development, axonal polarity formation and subcellular localization in
cultured mouse cortical neurons), a Nikon E80i equipped with a × 10
objective (for cortical migration and in utero electroporation (IUE)), a Nikon
A1 confocal microscope equipped with a × 20 objective (for neurite
outgrowth in rat hippocampal slice cultures and the IUE examples) and a
Nikon A1 confocal microscope equipped with a × 60 oil immersion lens (for
spine density).
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To evaluate neurite length in cultured primary cortical neurons, GFP-
positive cells were randomly selected from each condition, and the total
neurite length was traced with the Fiji software (http://imagej.net/Fiji/
Downloads). At least three independent experiments were performed, and
approximately 70 neurons were analyzed.
To evaluate spine density in rat hippocampal slice cultures, images were
obtained as a Z-stack of approximately 15–20 sections (0.2 μm per section).
The average spine density of speciﬁc neurons was analyzed statistically
and compared among the four treatments. The average spine density was
calculated as the total number of spines per 10 μm of dendritic length of
each neuron. Approximately 45 neurons from 3 independent experiments
were evaluated. The speciﬁc dendritic length was traced with the Fiji
software (http://imagej.net/Fiji/Downloads).
To analyze total neurite outgrowth in slice cultures, images were
obtained as a Z-stack of approximately 10–15 sections (1 μm per section).
The total neurite length of each neuron was then traced with the Fiji
software, as described previously.
For IUE, GFP-positive cells were counted using the ImageJ software
(https://imagej.nih.gov/ij/download.html). The ratio of GFP-positive cells in
the cortical plate included the total number of GFP-positive cells in the
intermediate zone, the subventricular zone and the ventricular zone and
was analyzed for each condition.
Figure 2. Wild-type (WT) Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) rescues the phenotype of decreased
neurites and axon length in cultured mouse cortical neurons following Dyrk1a short hairpin RNA (shRNA) knockdown. (a) The speciﬁc
morphology of neurons expressing the vectors (CAG and pSUPER), shRNA, WT Dyrk1a and WT or mutant forms of Dyrk1a along with the
shRNA. All neurons were co-labeled with 4,6-diamidino-2-phenylindole (DAPI), green ﬂuorescent protein (GFP) and SMI 312 (to distinguish
axons from total neurites). Scale bar 50 μm. (b, c) The statistical results for the total neurites (b) and axon length (c) between speciﬁc cell types.
The bar graph shows the mean value± s.e.m.; approximately 60 cells from three independent experiments were counted, and unpaired t-tests
were used for the statistical analysis. ***Po0.001, ****Po0.0001.
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All statistical analyses were conducted using unpaired t-tests, with
Po0.05 considered signiﬁcant.
RESULTS
Dyrk1a expression proﬁling during brain development
Dyrk1a is widely expressed in the developing nervous system,10,32
suggesting that it has a crucial role in brain development. To
examine DYRK1A protein levels in the embryonic and postnatal
cortex, we collected protein lysates from embryonic and early
postnatal mouse brains and examined DYRK1A protein levels via
western blotting. We found that Dyrk1a was highly expressed
during the embryonic stage, from E16 to P0, and this high
expression level persisted until P7 (Figure 1a). In contrast,
DYRK1A protein expression gradually decreased from P7 and
remained at a relatively low level thereafter (Figure 1a). This
Figure 3. Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) dosage imbalance reduced dendritic spine density in rat
hippocampal slice culture, and wild-type (WT) Dyrk1a rescued the phenotype caused by Dyrk1a knockdown. (a, c) Morphology of the spine
density under speciﬁc conditions with the expression of different plasmids, including CAG vector, Dyrk1a short hairpin RNA (shRNA), Dyrk1a
WT, R205X (a) and shRNA rescue using WT or mutant Dyrk1a (c). Scale bar 5 μm. (b, d) Statistical analysis of the spine density (per 10 μm) in
speciﬁc types of neurons. Forty-ﬁve neurons from three independent experiments were counted, and the individual neuronal spine density
was determined. Unpaired t-tests were performed for the statistical analysis to compare each condition. **Po0.01, ***Po0.001,
****Po0.0001.
Figure 4. Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) inhibited total neurite outgrowth in rat hippocampal
neurons, and short hairpin RNA (shRNA)-mediated loss of function was rescued by wild-type Dyrk1a. (a, c) The morphology of neurons in each
condition expressing the indicated plasmids. (a) Neurons expressed CAG vector, Dyrk1a short hairpin RNA (shRNA), Dyrk1a wild-type (WT) and
R205X. (c) Neurons expressed speciﬁc plasmids for the rescue conditions, including WT and the ﬁve mutant forms of Dyrk1a plus Dyrk1a
shRNA. (b, d) Statistical analysis of total neurite length in overexpression (b) and rescue conditions (d). Scale bar 50 μm. Approximately 50
neurons from three independent experiments were counted, and the total neurite length of each cell was determined. Unpaired t-tests were
performed for the statistical analysis. **Po0.01, ***Po0.001, ****Po0.0001.
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expression pattern suggests that Dyrk1a has a critical role in the
developing brain. To study the role of Dyrk1a in neural
development, we designed a series of shRNAs against the mouse
Dyrk1a gene and identiﬁed one set of effective shRNAs that
signiﬁcantly decreased DYRK1A protein levels in mouse primary
cortical neurons (Figure 1b).
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The dosage of Dyrk1a is crucial for dendritic growth in cultured
neurons
Dendrites have a vital role in the biological functions of neurons,
such as the receipt of information from other neurons. Previous
studies have observed dendritic abnormalities in the brains of DS
patients; in these patients, the DYRK1A gene is overexpressed
owing to the excess of chromosome 21-associated genes.15,18
Furthermore, Lepagnol-Bestel et al.21 showed that overexpressing
Dyrk1a in mouse cortical neurons signiﬁcantly decreased neurite
length. Thus we decided to investigate whether autism-associated
Dyrk1a mutations are involved in neurite development.
During our analysis of DYRK1A variants, we classiﬁed
the nine variants into three groups according to their speciﬁc
localization in the functional domains of DYRK1A (Figure 1c), as
described above, and decided to select ﬁve representative
mutants (R205X, E239X, H119Y, A195T and L259F) for further
analysis.
In this study, we transfected mouse primary cortical neurons
with plasmids expressing the empty CAG vector (as a control),
Dyrk1a shRNA, WT Dyrk1a and the ﬁve Dyrk1a mutants, and we
measured total neuritic and axonal length after 72 h. First, we
conﬁrmed a previous ﬁnding that overexpression of WT Dyrk1a
severely reduced the total neurite length in cultured mouse
cortical neurons (Figures 1d–f). Importantly, when endogenous
Dyrk1a was speciﬁcally knocked down by RNA interference (RNAi),
neurite length was also signiﬁcantly decreased compared with
control neurons expressing GFP alone. This ﬁnding was similar to
the observation that overexpressing WT Dyrk1a decreased neurite
growth (Figures 1d–f). These data indicate that the precise dosage
of DYRK1A protein is critical for proper neurite development.
We further examined whether mutations in Dyrk1a affected
neurite growth. We found that overexpressing either of the two
Dyrk1a truncation mutants (R205X and E239X) did not inhibit total
neurite growth; neurite growth in cells that were transfected with
these mutants resembled that of controls, indicating that these
two mutants lacked the normal function of WT Dyrk1a
(Figures 1d–e). However, all three Dyrk1a missense mutants
(H119Y, A195T and L259F) retained the ability to repress neurite
outgrowth when overexpressed (Figures 1d–e), similar to WT
Dyrk1a, indicating that non-haploinsufﬁcient mutations may affect
different aspects of brain development.
We next investigated whether Dyrk1a might affect axonal
growth in neurons. During the neurite development assay, we
measured axon length via immunohistochemistry using an
antibody against the axonal marker SIM 312 and found that
axonal growth was indeed affected by the Dyrk1a dosage and
autism-associated mutations (Figures 1d and f). From these results,
we found that shRNA-mediated Dyrk1a knockdown, as well as the
overexpression of the WT form and the three missense mutants,
decreased axon length compared with the control. In contrast,
R205X- and E239X-expressing neurons exhibited the same
phenotype as CAG vector-expressing neurons (Figures 1d and f).
Because WT Dyrk1a overexpression led to a similar phenotype
to that of shRNA-mediated Dyrk1a knockdown, we performed a
rescue experiment to conﬁrm the speciﬁcity of the shRNA-
mediated Dyrk1a knockdown and acquire a better understanding
of the critical impact of the Dyrk1a dosage on neurite and axonal
development. WT Dyrk1a rescued the inhibition of both neurite
and axon length caused by Dyrk1a RNAi (Figures 2a–c). Neurons
co-expressing WT Dyrk1a and shRNA exhibited similar outgrowth
as control neurons expressing GFP alone, conﬁrming the
speciﬁcity of the Dyrk1a shRNA in mouse cortical neurons.
Moreover, we previously showed that overexpression of
nonsense mutations did not mimic the phenotype of WT Dyrk1a
overexpression on neurite and axonal growth, revealing the
important effect of these two Dyrk1a truncations. For further
insight into the function of these mutants, we also conducted a
rescue experiment using the ﬁve mutant forms of Dyrk1a and
found that only the three missense mutations could rescue the
knockdown phenotype (Figures 2a–c). The two truncations, R205X
and E239X, did not restore neurite and axon lengths to control
levels. In fact, staining revealed decreased outgrowth, similar to
that observed with Dyrk1a RNAi (Figures 2a–c). Therefore, we
surmise that these two Dyrk1a truncations act as Dyrk1a loss-of-
function mutants.
We conclude that the Dyrk1a dosage is critical for proper
neurite and axonal outgrowth and that the two nonsense
mutations, R205X and E239X, are loss-of-function mutants.
Dyrk1a is crucial for the growth of neurites and spines in
hippocampal neurons in slices
Next we wanted to examine the role of Dyrk1a in spine formation
in hippocampal neurons. Dendritic spines are small protrusions
along dendrites and represent the typical postsynaptic structure
of excitatory synapses. Studies have shown that dendritic spine
abnormalities are strongly associated with various neurological
and neuropsychiatric disorders.33 Dyrk1a is reported to phosphor-
ylate and inactivate the N-WASP protein, suggesting that Dyrk1a
has a role in spine formation.12
We investigated the role of Dyrk1a in spine formation using a
hippocampal slice culture system. We used gene-gun-mediated
delivery to introduce plasmids encoding GFP along with WT
Dyrk1a, Dyrk1a R205X and Dyrk1a shRNA into hippocampal
neurons in postnatal hippocampal slices. Interestingly, we found
that either knocking down Dyrk1a or overexpressing the WT form
strongly repressed dendritic spine formation in hippocampal
neurons, further indicating that a precise amount of DYRK1A
protein is required for proper spine development (Figures 3a
and b). However, overexpression of the R205X mutant did not
similarly inhibit dendritic growth (Figures 3a and b).
Furthermore, we conducted rescue assays to conﬁrm the critical
role of Dyrk1a in spine formation. WT Dyrk1a successfully rescued
the loss of function, and neurons that received this treatment
exhibited phenotypes similar to those of neurons that only
expressed the CAG vector (Figures 3c and d). Therefore, we
concluded that the shRNA against Dyrk1a was speciﬁc in rat
hippocampal neuron. The three missense mutations also rescued
the decreased spine density caused by Dyrk1a RNAi, whereas
the two truncation mutants, R205X and E239X, did not rescue the
effects on spine formation (Figures 3c and d), consistent with the
rescue phenotype that was observed in mouse cortical neurons.
We also measured neurite outgrowth in hippocampal neurons
that received the aforementioned manipulations. Consistently,
either RNAi or WT Dyrk1a overexpression strongly inhibited
neurite growth in hippocampal neurons in brain slices
(Figures 4a and b). However, overexpression of the Dyrk1a
R205X mutant did not affect neurite growth compared with WT
Dyrk1a (Figures 4a and b). We next re-expressed WT and different
Dyrk1a mutants along with RNAi in hippocampal slice cultures to
assess whether these defects could be rescued. Only WT Dyrk1a
and the missense mutants, but not R205X and E239X, were able to
rescue the defects caused by RNAi (Figures 4c and d). The rescue
results further conﬁrmed the role of Dyrk1a in neurite develop-
ment in hippocampal slices and that the truncations resulted in
Dyrk1a loss of function. This evidence again indicates that the
autism-related Dyrk1a truncations (R205X and E239X) are loss-of-
function mutations.
Dyrk1a is critical for cortical migration during early postnatal
development
To further understand the role of Dyrk1a in embryonic and
postnatal cortical development in the mouse brain, we examined
cortical migration by manipulating Dyrk1a via IUE in mice.
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Figure 5. Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) wild-type (WT) overexpression delayed neuronal
migration in mouse embryonic cortical development. (a) Cortical migration in each condition, including CAG (left), Dyrk1a WT overexpression
(middle) and R205X (right). (b) Quantiﬁcation of panel (a). The green ﬂuorescent protein (GFP)-positive cells in the cortical plate (CP),
intermediate zone (IZ), subventricular zone (SVZ) and ventricular zone (VZ) were counted, and the ratio of GFP-positive cells in the CP/(IZ and
VZ/SVZ) was analyzed statistically using unpaired t-tests. P0 mice were collected in three independent experiments, including CAG (n= 7),
Dyrk1A WT (n= 6) and R205X (n= 5) mice. ****Po0.0001. Scale bar 100 μm.
Figure 6. The two Dyrk1a (dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 1 A) truncations did not disturb Dyrk1a subcellular
localization. (a–e) Neurons expressing Dyrk1a wild-type (WT) were labeled with 4,6-diamidino-2-phenylindole (DAPI; to identify nuclei), a Myc
epitope tag (to identify the precise location of the expressed protein) and green ﬂuorescent protein (GFP; to identify overall neuronal
morphology). Merge 1 shows DAPI and Myc co-labeling, and merge 2 shows DAPI, Myc and GFP labeling. Panels (f–j) and (k–o) depict the two
nonsense mutants, respectively. Both R205X and E239X, as well as Dyrk1a WT, localized to the nucleus. The images were merged using the
ImageJ software. Scale bar 20 μm.
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Plasmids encoding GFP plus either the WT Dyrk1a or the R205X
mutant were electroporated into the ventricular zone of E14.5
mouse brains, and the migration status of the GFP-labeled
neurons was observed in neonatal pups on P0. Overexpression
of WT Dyrk1a signiﬁcantly delayed cortical migration compared
with GFP expression alone (Figures 5a and b). In contrast,
expressing the Dyrk1a R205X truncation in migrating neurons
did not similarly affect cortical migration, again suggesting that
the R205X truncation has a loss-of-function effect (Figures 5a
and b). This evidence again indicates that the R205X truncation
may be a loss-of-function mutant of Dyrk1a, which affects various
aspects of postnatal neural development, including dendrite and
spine formation and cortical migration.
Autism-related Dyrk1a truncations do not affect subcellular
localization
The histidine-repeat domain near the C-terminus of DYRK1A is
critical for its localization in nuclear speckles.34 Therefore, we
wanted to examine whether the R205X or E239X truncation
affected the subcellular localization of Dyrk1a in neurons. We
transfected cultured mouse primary cortical neurons with
plasmids encoding myc-tagged WT Dyrk1a or the two truncated
mutants. By performing immunocytochemistry with an anti-myc
antibody, we ﬁrst conﬁrmed that WT Dyrk1a was expressed
exclusively in the nucleus (Figure 6). Importantly, the R205X and
E239X Dyrk1a truncations were also located in the nucleus,
suggesting that these mutations did not affect Dyrk1a localization
(Figure 6).
DISCUSSION
DYRK1A is a critical gene located on human chromosome 21,
encoding a proline-directed serine/threonine kinase that has been
reported to phosphorylate several substrates related to gene
transcription, neuronal degeneration and synapse function.9
Dyrk1a transgenic mice (TgDyrk1A), a mouse model of DS that
overexpresses Dyrk1a by 1.5-fold,19 show defects in learning and
memory, as well as hyperactivity and altered motor learning.22
Duplications of Dyrk1a result in abnormal neural development,
such as compromised dendrite outgrowth and cell differentiation.
At early embryonic stages, Dyrk1a overexpression reduces the
proliferation of neuronal progenitor cells,35–40 whereas increasing
neuronal differentiation and enhancing GABAergic differentiation,
which were observed in neuronal stem cells isolated from
TgDyrk1A mice.
For decades, different types of genetic/genomic defects have
been linked to ASD, including chromosomal abnormalities,
genomic copy number variants and genetic variants of hundreds
genes, highlighting the etiological heterogeneity underlying the
genetic and phenotypic variation in ASD. Recently, DYRK1A was
proposed as a candidate gene for syndromic ASD and ID or DD,
and approximately 100 alterations have thus far been identiﬁed.
Of these, the majority are de novo heterozygous mutations
(nonsense, frame-shift, splicing alteration) and large chromosomal
rearrangements (micro-deletion/duplication, insertion and trans-
location). The majority were haploinsufﬁciency alterations, which
are relevant for many ASD-associated genes. The eight novel and
one recurrent DYRK1A mutations detected in our patients with
ASD/ID/DD are consistent with these ﬁndings.6,8,24–26,41–44
In the present study, the phenotypes of the two patients with
DYRK1A truncations partially overlapped with the ﬁndings in a
recent report, including microcephaly, seizures and impaired
speech, supporting the hypothesis that DYRK1A truncations deﬁne
a syndromic form of ASD and ID.26 Interestingly, the higher
incidence of truncations identiﬁed in our patients (0.22%; 2
truncations in 892 patients) is similar to work by van Bon et al.26
(0.21%; 15 truncations in 7162 patients), further supporting the
observation that DYRK1A truncations may be a relatively common
type of mutation associated with syndromic ASD and ID or DD.
Fewer than 10 missense mutations have been reported in the
literature, and most are predicted to be pathogenic; however, no
functional studies have been described. In the present study, we
found that the three missense mutations behaved similarly to WT
Dyrk1a when overexpressed, with all three repressing neurite and
axon outgrowth and affecting spine development; however, all
could be rescued, which indicated that they were not loss-of-
function mutations but may affect other Dyrk1a functions that
were not assessed in this study. These ﬁndings also suggested that
non-haploinsufﬁcient missense mutations may affect brain devel-
opment in different ways than haploinsufﬁcient truncated
mutations. Further studies to explore the pathogenesis of such
missense mutations are needed. In addition, this study was limited
to detecting only DYRK1A mutations; therefore, these missense
mutations may in fact function with other unknown mutations or
may not contribute to the risk of autism.
In this study, we show that Dyrk1a has an important role in
neural development. The imbalance of the Dyrk1a dosage affected
dendrite development and axon length. Consistent results were
found in primary cultured mouse cortical neuron and rat
hippocampal slice cultures. We also found that the two Dyrk1a
nonsense truncations were unable to rescue defects caused by
Dyrk1a knockdown. Therefore, we conclude that nonsense
mutations caused a loss of function of the DYRK1A protein, which
had effects on dendritic outgrowth in neurons, dendritic spine
development and embryonic cortical migration. Moreover, upre-
gulation and downregulation of Dyrk1a also reduced the dendritic
spine density in rat hippocampal slice cultures. Importantly,
cortical migration during the mouse embryonic stage was also
altered by the overexpression of WT Dyrk1a from E14.5 to P0.
Based on these results, we conclude that Dyrk1a has a key role in
embryonic development.
Furthermore, overexpression of the two nonsense truncations
resembled defects caused by Dyrk1a knockdown, suggesting that
patients carrying Dyrk1a nonsense mutations show haploinsufﬁ-
ciency of Dyrk1a. Reduced DYRK1A proteins levels of in patients
likely lead to defects in neural development and further ASD
symptoms, providing new evidence that the dosage of Dyrk1a is
critical for proper neurite and axonal outgrowth.
To date, the impact of Dyrk1a loss of function on neural
development remains limited. For example, mice expressing only
one copy of Dyrk1a exhibit a microcephalic phenotype.45,46
However, the functional consequences of Dyrk1a loss of function
have not been fully addressed. Dyrk1a knockout was reported to
be lethal during the embryonic period, whereas Dyrk1a+/− mice
survive but display severe defects in cognition, DDs and
abnormalities in brain size and structure.47,48 Thus it is difﬁcult
to undertake further analyses of this gene in a loss-of-function
mouse model. The two Dyrk1a truncations we found in ASD
patients provide important insights into the role of loss-of-function
forms of Dyrk1a in various aspects of neural development.
DYRK1A phosphorylates multiple substrates. For instance, P53
Ser15 is directly phosphorylated by DYRK1A, and P53 phosphor-
ylation at this site inhibits the proliferation of neural progenitors.10
DYRK1A has been shown to selectively phosphorylate RCAN1 at
Ser112, prompting the phosphorylation of another residue,
Ser108, by GSK3β and resulting in the formation of insoluble
aggregates that contribute to the development of Alzheimer
disease.11 N-WASP Thr192 may also be a substrate for DYRK1A
phosphorylation, and spine formation can be inhibited by
phosphorylation at this site.12 DYRK1A phosphorylates Tau at
multiple sites, leading to decreased microtubule assembly and the
formation of interneuron aggregates.13,23 These observations
reveal the potential role of Dyrk1a in dendritic outgrowth. In
addition, DYRK1A negatively regulates nuclear factor of activated
T cells by phosphorylating the serine-proline repeats 3 domain.49
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Further studies are required to illustrate the exact substrates of
DYRK1A that are responsible for various aspects of neural
development.
In the present study, we showed that both excessive and
reduced Dyrk1a activity yield similar phenotypes of delayed neural
development that were distinct from the phenotypes associated
with other candidate genes in neurodevelopment.50 Although
ASD and DS are both neuronal development disorders and
although previous studies have mostly focused on the relationship
between DYRK1A and DS,9,15,21,23 there are essential differences
between ASD and DS. For example, the incidence stage and the
speciﬁc phenotypes differ; severe mental retardation and delayed
development is observed in DS patients, whereas verbal dysfunc-
tion and social problems are often observed in ASD patients.2
Genes in the DSCR region of chromosome 21 have clear
connections with DS, whereas genetic factors other than
chromosome 21 are associated with ASD. Thus it is important
and necessary to identify the mechanisms by which DYRK1A
contributes to ASD.
In summary, we found that Dyrk1a strongly affected various
aspects of neuronal development, such as dendritic outgrowth,
dendritic spine density and cortical migration, during early
postnatal development. Importantly, R205X and E239X, two
DYRK1A truncations that were identiﬁed in ASD/ID/DD patients,
functioned as loss-of-function mutants.
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